Free Trial
→ I'm giving you a space stock today. Free. (From Behind the Markets) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
$13.95
-15.7%		$18.88
$12.99
▼
$25.59
$1.47B0.421.95 million shs6.80 million shs
Defiance Trillion Dollar Club Index ETF stock logo
TRIL
Defiance Trillion Dollar Club Index ETF
$19.86
$18.12
$5.80
▼
$20.96
$2.09B2.081.87 million shsN/A
10 Best Stocks to Own in Fall 2026 Cover
10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
-15.71%-19.69%-23.27%-40.69%-8.22%
Defiance Trillion Dollar Club Index ETF stock logo
TRIL
Defiance Trillion Dollar Club Index ETF
0.00%0.00%0.00%0.00%+1.70%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
$13.95
-15.7%		$18.88
$12.99
▼
$25.59
$1.47B0.421.95 million shs6.80 million shs
Defiance Trillion Dollar Club Index ETF stock logo
TRIL
Defiance Trillion Dollar Club Index ETF
$19.86
$18.12
$5.80
▼
$20.96
$2.09B2.081.87 million shsN/A
10 Best Stocks to Own in Fall 2026 Cover
10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
-15.71%-19.69%-23.27%-40.69%-8.22%
Defiance Trillion Dollar Club Index ETF stock logo
TRIL
Defiance Trillion Dollar Club Index ETF
0.00%0.00%0.00%0.00%+1.70%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
2.82
Moderate Buy$41.80199.64% Upside
Defiance Trillion Dollar Club Index ETF stock logo
TRIL
Defiance Trillion Dollar Club Index ETF
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest TRIL and SNDX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/13/2026
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$38.00
10/2/2026
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (E+) ➝ Sell (D-)
10/1/2026
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy
10/1/2026
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy
9/29/2026
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$35.00
9/16/2026
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeSell (D-) ➝ Sell (E+)
8/21/2026
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (E+) ➝ Sell (D-)
8/21/2026
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetBuy$37.00 ➝ $33.00
8/11/2026
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetOverweight$44.00 ➝ $40.00
8/5/2026
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
Bank of America Corporation logo
Bank of America
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy
(Data available from 10/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
$172.35M7.17N/AN/A$0.74 per share18.85
Defiance Trillion Dollar Club Index ETF stock logo
TRIL
Defiance Trillion Dollar Club Index ETF
$150K13,903.44N/AN/A$2.56 per share7.76
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
-$285.42M-$2.51N/AN/AN/A-87.52%-372.94%-39.11%11/2/2026 (Estimated)
Defiance Trillion Dollar Club Index ETF stock logo
TRIL
Defiance Trillion Dollar Club Index ETF
-$59.35M$0.6232.04N/AN/AN/A-23.31%-18.66%N/A

Latest TRIL and SNDX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/2/2026Q3 2026
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
-$0.4848N/AN/AN/A$82.41 millionN/A
8/4/2026Q2 2026
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
-$0.4477-$0.55-$0.1023-$0.55$79.36 million$72.79 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
N/AN/AN/AN/AN/A
Defiance Trillion Dollar Club Index ETF stock logo
TRIL
Defiance Trillion Dollar Club Index ETF
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
38.95
6.77
6.44
Defiance Trillion Dollar Club Index ETF stock logo
TRIL
Defiance Trillion Dollar Club Index ETF
N/A
19.82
19.82

Institutional Ownership

CompanyInstitutional Ownership
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
N/A
Defiance Trillion Dollar Club Index ETF stock logo
TRIL
Defiance Trillion Dollar Club Index ETF
87.15%

Insider Ownership

CompanyInsider Ownership
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
4.80%
Defiance Trillion Dollar Club Index ETF stock logo
TRIL
Defiance Trillion Dollar Club Index ETF
9.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
29888.61 million84.36 millionOptionable
Defiance Trillion Dollar Club Index ETF stock logo
TRIL
Defiance Trillion Dollar Club Index ETF
33105.00 million95.44 millionNo Data

Recent News About These Companies

Direxion files for Trillions ETF to track equities over $1T, including 2x leveraged version
September 3, 2026  |  cryptobriefing.comC
The Trillion-Dollar Club: Mega-Cap Stocks With Market Caps Over $1 Trillion
June 17, 2026  |  money.usnews.comhttps://money.usnews.com/investing/articles/the-trillion-dollar-club-mega-cap-stocks-with-market-caps-over-1-trillion
ETF Prime: Murphy on the New Faces of the ETF Boom
October 29, 2025  |  etftrends.comE
Defiance Trillion Dollar Club Index ETF
October 21, 2025  |  money.usnews.comhttps://money.usnews.com/funds/etfs/technology/defiance-trillion-dollar-club-index-etf/tril
Tidal Trust II - Defiance Trillion Dollar Club Index ETF
October 16, 2025  |  money.usnews.comhttps://money.usnews.com/investing/stocks/tril-tidal-trust-ii-defiance-trillion-dollar-club-index-etf/vitals
Trillion-Dollar Inflows: ETFs Become the Market’s New “Pulse”
October 16, 2025  |  nai500.comN
The Future Of Psychedelic-Inspired Therapeutics: No-Trip Neuroplastogens
August 14, 2025  |  lifescienceleader.comL
Pfizer Ends Mid-Stage Trial for CD47 Blood Cancer Drug, Citing Recruitment Problems
July 1, 2025  |  biospace.comB
Ratio Therapeutics and TerraPower Isotopes Sign Supply Agreement for Actinium-225 For Targeted Radiotherapeutics
June 20, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/ratio-therapeutics-terrapower-isotopes-sign-120000049.html
Trillium Therapeutics Stock Price History
May 26, 2025  |  investing.comhttps://www.investing.com/equities/stem-cell-therapeutics-corp.-historical-data
TTI Consumer Power Tools, Inc. is Seeking an IP Paralegal
September 26, 2024  |  ipwatchdog.comI
Advances in Drug Discovery & Development 2024
September 8, 2024  |  technologynetworks.comT
When You Look Back in 5 Years, You'll Wish You'd Bought This $2 Trillion Artificial Intelligence (AI) Stock
July 30, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/look-back-5-years-youll-101100218.html
Google Cloud unveils the Trillium TPU, its most powerful AI processor so far
May 14, 2024  |  siliconangle.comS
Rejuvenate your look with a trip to Fourth Avenue Medical Aesthetics
January 30, 2024  |  chch.comC
TTI apprehends motorists for illegal removal of clamps, hunt for four others underway
January 30, 2024  |  bulawayo24.comB
BridgeBio raises $1.25bn, and other biotech financings
January 19, 2024  |  pharmaphorum.comP
Ratio Therapeutics Raises $50M in Series B Financing
January 17, 2024  |  precisionmedicineonline.comP
Leiomyosarcoma Drug Pipeline Report 2023 - ResearchAndMarkets.com
November 10, 2023  |  businesswire.comhttps://www.businesswire.com/news/home/20231110258104/en/
Mirati Therapeutics Stock (NASDAQ:MRTX), Analyst Ratings, Price Targets, Predictions
November 8, 2023  |  benzinga.comhttps://www.benzinga.com/quote/MRTX/analyst-ratings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Syndax Pharmaceuticals stock logo

Syndax Pharmaceuticals NASDAQ:SNDX

$13.95 -2.60 (-15.71%)
As of 10/13/2026 04:00 PM Eastern

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

Defiance Trillion Dollar Club Index ETF stock logo

Defiance Trillion Dollar Club Index ETF NASDAQ:TRIL

Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas